Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial

Messoud Ashina; Peter J. Goadsby; Uwe Reuter; Stephen Silberstein; David W. Dodick; Fei Xue; Feng Zhang; Gabriel Paiva Da Silva Lima; Sunfa Cheng; Daniel D. Mikol

doi:10.1111/ene.14715

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial

Messoud Ashina, Peter J. Goadsby, Uwe Reuter, Stephen Silberstein, David W. Dodick, Fei Xue, Feng Zhang, Gabriel Paiva Da Silva Lima, Sunfa Cheng, Daniel D. Mikol

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

133 Citationer (Scopus)

18 Downloads (Pure)

Originalsprog	Engelsk
Tidsskrift	European Journal of Neurology
Vol/bind	28
Udgave nummer	5
Sider (fra-til)	1716-1725
Antal sider	10
ISSN	1351-5101
DOI	https://doi.org/10.1111/ene.14715
Status	Udgivet - 1 maj 2021

Adgang til dokumentet

10.1111/ene.14715Licens: CC BY-NC

ene.14715Forlagets udgivne version, 886 KBLicens: CC BY-NC

Citationsformater

Ashina, M., Goadsby, P. J., Reuter, U., Silberstein, S., Dodick, D. W., Xue, F., Zhang, F., Paiva Da Silva Lima, G., Cheng, S., & Mikol, D. D. (2021). Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial. European Journal of Neurology, 28(5), 1716-1725. https://doi.org/10.1111/ene.14715

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial. / Ashina, Messoud; Goadsby, Peter J.; Reuter, Uwe et al.
I: European Journal of Neurology, Bind 28, Nr. 5, 01.05.2021, s. 1716-1725.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Ashina, M, Goadsby, PJ, Reuter, U, Silberstein, S, Dodick, DW, Xue, F, Zhang, F, Paiva Da Silva Lima, G, Cheng, S & Mikol, DD 2021, 'Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial', European Journal of Neurology, bind 28, nr. 5, s. 1716-1725. https://doi.org/10.1111/ene.14715

@article{de206c7096084320bb102c59ff7123ff,

title = "Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial",

author = "Messoud Ashina and Goadsby, {Peter J.} and Uwe Reuter and Stephen Silberstein and Dodick, {David W.} and Fei Xue and Feng Zhang and {Paiva Da Silva Lima}, Gabriel and Sunfa Cheng and Mikol, {Daniel D.}",

year = "2021",

month = may,

day = "1",

doi = "10.1111/ene.14715",

language = "English",

volume = "28",

pages = "1716--1725",

journal = "European Journal of Neurology",

issn = "1351-5101",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial

AU - Ashina, Messoud

AU - Goadsby, Peter J.

AU - Reuter, Uwe

AU - Silberstein, Stephen

AU - Dodick, David W.

AU - Xue, Fei

AU - Zhang, Feng

AU - Paiva Da Silva Lima, Gabriel

AU - Cheng, Sunfa

AU - Mikol, Daniel D.

PY - 2021/5/1

Y1 - 2021/5/1

U2 - 10.1111/ene.14715

DO - 10.1111/ene.14715

M3 - Journal article

C2 - 33400330

SN - 1351-5101

VL - 28

SP - 1716

EP - 1725

JO - European Journal of Neurology

JF - European Journal of Neurology

IS - 5

ER -